Arcellx Inc.
Arcellx Announces Positive Data from Phase 2 iMMagine-1 Study for RRMM Treatment
Summary
Arcellx, Inc. has announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. The study data, cut off as of October 7, 2025, showed a 96% overall response rate and 74% complete response rate at a median follow-up of 15.9 months. Additionally, the company is set to present the updated clinical data at the 67th American Society of Hematology Annual Meeting on December 6, 2025. A press release detailing these results is attached as Exhibit 99.1.
Profitelligence Alerts
Get alerts for ACLX
Be first to know when Arcellx Inc. files with the SEC.
Filing Categories
Advertisement
About Arcellx Inc.
Arcellx Inc. is a biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of cancer and other debilitating diseases. The company's primary goal is to harness the power of the immune system through its proprietary D-Domain technology platform, which is designed to improve the efficacy and safety of cell-based treatments. Arcellx focuses on targeting malignant cells with precision, thereby enhancing therapeutic outcomes and minimizing adverse effects. Operating within the highly complex and rapidly evolving biotechnology sector, Arcellx significantly contributes to advancements in life sciences and medical treatments. Given its commitment to pioneering scientific discoveries, the company represents a significant player in the push towards personalized medicine and novel cancer therapies. Through collaboration with academic institutions and strategic partnerships, Arcellx endeavors to accelerate the development and commercialization of its pipeline products, aiming to bring life-changing treatments to patients worldwide. Its research-intensive approach and focus on addressing unmet medical needs position Arcellx as an impactful entity in the biopharmaceutical landscape.
Official SEC Documents
Advertisement